







Alzheimer's Disease Research

MAC Clinical Research brings extensive experience in Alzheimer's disease and other dementia-related disorders, having conducted over 90 studies across this therapeutic area. Our expertise is rooted in our origins as one of Europe's first Memory Assessment Centres, establishing a long-standing commitment to dementia and Alzheimer's research. This unique heritage, combined with our proven CRO operational capabilities, positions MAC as a partner of choice for sponsors seeking high-quality, reliable delivery in Alzheimer's clinical studies.

Experience in Alzheimer's Disease & Dementia



Some companies we have partnered with for studies in Alzheimer's Disease



Alzheimer's Disease treatments we've worked on

- Hydromethylthionine mesylate (HMTM) an oral tau aggregation inhibitor which delivers Hydromethylthionine (HMT).
- Oral beta-secretase 1 cleaving enzyme (BACE) inhibitor.
- RVT-101 (intepirdine), an investigative 5-HT6 receptor antagonist developed to treat Alzheimer's disease and Dementia with Lewy Bodies (DLB) by increasing brain acetylcholine levels.
- Elenbecestat (E2609), an investigational, oral BACE1 inhibitor.
- A dual M1/M4 agonist targeting Alzheimer's psychosis.
- Selective p38 MAP Kinase Alpha Inhibitor Neflamapimod, a p38 MAP kinase alpha enzyme inhibitor.
- Selective M4 muscarinic receptor agonist Gantenerumab is an investigational fully human monoclonal antibody designed to treat Alzheimer's disease by targeting and removing amyloid-beta (Aβ) plaques from the brain.
- Orally available small-molecule activator of the sigma-1 receptor (SIGMAR1).

MAC has contributed to the development of several treatments that are now licensed, including the cholinesterase inhibitors Aricept (donepezil), Exelon (rivastigmine) and galantamine (Reminyl).

Strategically Positioned for Rapid Start-Up

MAC Clinical Research offers a unique proposition within the CRO landscape by owning and operating a comprehensive network of ten dedicated research sites across the UK as well as contracting with sites across the globe. This integrated infrastructure enables us to deliver true Full-Service clinical development solutions across Phases I-IV.

Our UK footprint provides access to **over 35 million people** within a 20-minute radius of our owned sites, supporting rapid and reliable patient recruitment. This capability is further strengthened by EnVision®, our proprietary patient recruitment database containing more than 280,000 pre-profiled individuals.


Together, these assets form our highly effective "Hub & Spoke" site model, designed to maximise patient accessibility, improve engagement, and ensure consistent, high-quality delivery across all programmes.



Case Studies in Alzheimer's Disease

AD Patient Recruitment - Phase II


- MAC provided recruitment boost 12 months into the study
- **Enrolled 88 patients**
 - 27.5% of global study population
 - From just 3 sites
- Significantly reduced the study timeline
- Reliable and significant contribution
- Cost effective





AD Patient Recruitment - Phase II

- MAC-owned sites were the top 2 recruiting sites (across all countries/sites)
- MAC recruited more patients than sites in Germany or Finland
 - UK randomized 31% of all study patients (N=94), of which 44% were from MAC-owned sites
- MAC randomized 13% of all patients (N=308)

Screening & Randomisation Frequency




Top Recruiters Exceeding the Baseline Commitment of 7 Patients



Mild Cognitive Impairment (MCI) - Phase IV

- Mild Cognitive Impairment Study involving frail patients over 75 years of age
- Strategy: Enhanced Recruitment Package by MAC's Patient Recruitment Centre providing many robust initiatives
 - Number of Respondents = 423
 - Number of Pre-Study (Chat) Visits = 148
 - Total Patients Screened = 35 (24 Screened within 4 weeks)
 - Total Screen Fails = 6
 - Total Patients Randomized = 26
 - Total MAC Sites = 7

Participants Screened



MAC Clinical Research

- ✓ Over 30 years' experience in conducting clinical studies
- ✓ Full-service CRO with global reach
- ✓ 10 fully-owned research facilities in the UK
- ✓ Experts in healthy volunteer and patient recruitment



5-year summary

120+

SPONSORS

250+

STUDIES

50+

INDICATIONS

20+

FIH STUDIES

Our Services



CLINICAL RESEARCH SERVICES

Project Management

Clinical Operations

Site Monitoring
Site Management
Trial Feasibility

Pharmacovigilance

Regulatory Affairs

Biometrics

EDC
Data Management
SAS Programming
Biostatistics
Medical Writing

Vendor Management

Randomization and Trial Supply Management

Digital Solutions

Electronic Patient-Reported Outcomes (ePRO)
eConsent

Medical Monitoring



SITE & PATIENT SERVICES

Participant Recruitment

Participant Retention

Global Investigator Sites

Network of Fully-Owned Investigator Sites

Sleep Laboratory
Early Phase Unit
Psychedelic Testing Suites
Phase I - IV Research Facilities
Memory Assessment Research Centre



SCIENTIFIC SOLUTIONS

Human Models of Disease

Scientific and Endpoint Assessments

Cardiovascular Assessments
Cognitive and Neuropsychological Assessments
Dermatology Assessments
Imaging Assessments
Neurophysiology Assessments

Clinical Procedures

Sleep Assessments

Psychodelics

Training



PHARMACEUTICAL SERVICES

GMP Manufacturing

In-House Pharmacy

Global Clinical Supplies

QP Services

IMP Management & Distribution

Controlled Drug Services

Laboratory Services

Clinical Pathology
Bioanalytical Services



STRATEGIC CONSULTANCY

Therapeutic Area Expertise & Study Development

Scientific Solutions & Pharmacodynamics

Clinical Science & Development

Medical Strategy, Input & Expertise

Statistical Analysis, Planning & Advice

Medical Writing

Laboratory Study Design, Methods & Conduct

Follow us on social



Visit macplc.com for more information